Import Alert On Drugs From Ranbaxy’s Plants Includes OTC Product
This article was originally published in The Tan Sheet
Executive Summary
India's largest drug maker, Ranbaxy, faces a hurdle to growing its U.S. business with FDA's ban on imports of some of its products, including an OTC drug
You may also be interested in...
Ranbaxy’s Private-Label Loratadine OTCs Spared By FDA Probe
Several first-to-file abbreviated new drug applications are on the line as Ranbaxy tries to resolve data integrity issues with FDA concerning its Paonta Sahib, India, facility
Ranbaxy’s Private-Label Loratadine OTCs Spared By FDA Probe
Several first-to-file abbreviated new drug applications are on the line as Ranbaxy tries to resolve data integrity issues with FDA concerning its Paonta Sahib, India, facility
Ranbaxy’s Private-Label Loratadine OTCs Spared By FDA Probe
Several first-to-file abbreviated new drug applications are on the line as Ranbaxy tries to resolve data integrity issues with FDA concerning its Paonta Sahib, India, facility